Ranbaxy Laboratories Ltd

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.

Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.

Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, said on Wednesday that its $3.2-billion (Rs 19,840 crore at 1 dollar = 62 rupees) acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.

Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it will sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.

India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.

Ipca had voluntarily halted shipments to the United States from the plant in July last year after the FDA outlined half a dozen violations including data integrity issues.

The Competition Commission of India (CCI) on Monday said it has approved generic drug maker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.

European authorities inspected all units at Ranbaxy's Dewas plant, in Madhya Pradesh, in June and did not approve the manufacturing practices at the unit that makes injectable cephalosporin antibiotics, Ranbaxy said in a stock market filing on Thursday.

Ranbaxy had filed a lawsuit against the US Food and Drug Administration last week for revoking tentative approvals it gave the company to make generics of Valcyte and Nexium.

The changes have been made on "account of proposed scheme of amalgamation with Sun Pharmaceuticals Industries Ltd," As per the changes announced today by India Index Services & Products Ltd (IISL), a subsidiary of NSE Strategic Investment Corporation Ltd.

The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.

Sun Pharma, which last year bought domestic peer Ranbaxy Laboratories Ltd in July, said it may sell low-margin businesses it deemed do not hold long-term value.

Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.

Sun Pharmaceutical Industries Ltd, India's largest drug maker, said on Monday that its revenue in fiscal year 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

Sun Pharmaceutical Industries Ltd, India's largest drug maker by sales, said on Wednesday that its $3.2-billion (Rs 19,840 crore at 1 dollar = 62 rupees) acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.

Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it will sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.

India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.

Ipca had voluntarily halted shipments to the United States from the plant in July last year after the FDA outlined half a dozen violations including data integrity issues.

The Competition Commission of India (CCI) on Monday said it has approved generic drug maker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.

European authorities inspected all units at Ranbaxy's Dewas plant, in Madhya Pradesh, in June and did not approve the manufacturing practices at the unit that makes injectable cephalosporin antibiotics, Ranbaxy said in a stock market filing on Thursday.

Ranbaxy had filed a lawsuit against the US Food and Drug Administration last week for revoking tentative approvals it gave the company to make generics of Valcyte and Nexium.

The changes have been made on "account of proposed scheme of amalgamation with Sun Pharmaceuticals Industries Ltd," As per the changes announced today by India Index Services & Products Ltd (IISL), a subsidiary of NSE Strategic Investment Corporation Ltd.